Synta Technology Corporation
GPTKB entity
Statements (117)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired_by_Mediwound_in_2016
|
| gptkbp:awards |
Various industry awards
|
| gptkbp:CEO |
Dr._R._D._H._Hsu
|
| gptkbp:clinicalTrials |
Community outreach programs
Public awareness campaigns Collaboration with tech companies Engagement with stakeholders Partnerships with non-profits Data visualization techniques Informed consent processes Ethical standards in research Clinical trial protocols Longitudinal studies Data analytics in research Diversity in clinical trials Collaboration with academic institutions Collaboration with health organizations Patient education initiatives Use of social media for recruitment Data sharing agreements Patient engagement strategies Patient feedback mechanisms Patient recruitment for trials Collaboration with hospitals Patient recruitment strategies Focus on health disparities Patient monitoring technologies Patient safety monitoring Data integrity measures Long-term follow-up studies Real-world evidence studies Phase 3 trials for new drugs Blockchain for data security Statistical analysis plans Collaboration with regulatory agencies Adverse event reporting Ethical considerations in trials Transparency in research practices Conducts clinical research trials Adaptive trial designs Biostatistics support Clinical trial registries participation Collaboration with CROs Collaboration with patient groups Data analysis for trial results Data collection for drug efficacy Ethics committee approvals Focus on patient outcomes. Focus on patient-centered outcomes Funding for clinical studies Global clinical trial initiatives Health economics assessments Monitoring of trial sites Patient advocacy involvement Patient demographics analysis Patient-centric trial designs Patient-reported outcomes measures Phase 1 trials for STA-4783 Phase 2 trials for STA-9090 Publication of trial results Quality assurance in trials Regulatory compliance in trials Regulatory submissions for trials Remote monitoring in studies Safety assessments in trials Telemedicine in clinical trials Trial design innovations Use of artificial intelligence in trials Use of biomarkers in trials Use of mobile apps in trials Use of surveys in research Use of technology in trials Use of wearables in studies |
| gptkbp:collaborations |
Partnerships with pharmaceutical companies
|
| gptkbp:communityEngagement |
Involvement in local community initiatives
|
| gptkbp:conference |
Participation in biotech conferences
|
| gptkbp:dissolved |
2016
|
| gptkbp:employees |
50-100
|
| gptkbp:focus |
Cancer therapeutics
|
| gptkbp:focusArea |
Oncology
Chronic diseases Rare diseases |
| gptkbp:founded |
2007
|
| gptkbp:founder |
Dr._R._D._H._Hsu
|
| gptkbp:funding |
Over $100 million raised
|
| gptkbp:headCoach |
Approximately 75
|
| gptkbp:headquarters |
gptkb:Lexington,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synta Technology Corporation
|
| gptkbp:industry |
Biotechnology
|
| gptkbp:innovation |
Focus on innovative therapies
|
| gptkbp:investmentFocus |
Venture capital firms
|
| gptkbp:keyPeople |
gptkb:Kathy_H._H._Hsu
|
| gptkbp:location |
gptkb:Lexington
gptkb:United_States gptkb:Massachusetts |
| gptkbp:market |
$50 million at peak
|
| gptkbp:partnerships |
Collaboration with various research institutions
|
| gptkbp:patentCitation |
Multiple patents in drug development
|
| gptkbp:products |
STA-4783
STA-9090 |
| gptkbp:publications |
Research publications in journals
|
| gptkbp:researchAreas |
Immuno-oncology
Targeted therapies Small molecule drugs |
| gptkbp:researchFocus |
Drug discovery
Preclinical studies Clinical development |
| gptkbp:sells |
NASDAQ:_SNTA
|
| gptkbp:socialResponsibility |
Commitment to ethical practices
|
| gptkbp:subsidiary |
Synta_Pharmaceuticals_Corp.
|
| gptkbp:successor |
gptkb:MediWound_Ltd.
|
| gptkbp:technology |
Biologics development
Advanced drug delivery systems Small molecule synthesis |
| gptkbp:type |
Public
|
| gptkbp:website |
www.syntatech.com
|